DOCSLIB.ORG

Montelukast and Neuropsychiatric Events in Children with Asthma: a Nested Case-Control Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Montelukast and Neuropsychiatric Events in Children with Asthma: a Nested Case-Control Study ORIGINAL ARTICLES Montelukast and Neuropsychiatric Events in Children with Asthma: A Nested Case–Control Study S. Dresden Glockler-Lauf, MPH1, Yaron Finkelstein, MD1,2,3,4,5, Jingqin Zhu, MSc1,2, Laura Y. Feldman, MPH1, and Teresa To, PhD1,2,6 Objective To examine the association between montelukast prescription and neuropsychiatric events in children with asthma. Study design A matched, nested case–control design was used to identify cases and controls from a cohort of children aged 5-18 years with physician-diagnosed asthma from 2004 to 2015, in Ontario, Canada, prescribed an asthma maintenance medication. Cases were children with a hospitalization or emergency department visit for a neuropsychiatric event. Cases were matched to up to 4 controls on birth year, year of asthma diagnosis, and sex. The exposures were dispensed prescriptions for montelukast (yes/no) and number of dispensed montelukast prescriptions in the year before the index date. Conditional logistic regression was used to measure the unadjusted OR and aOR and 95% CIs for montelukast prescription and neuropsychiatric events. Covariates in the adjusted model included sociodemographic factors and measures of asthma severity. Results In total, 898 cases with a neuropsychiatric event and 3497 matched controls were included. Children who experienced a new-onset neuropsychiatric event had nearly 2 times the odds of having been prescribed montelu- kast, compared with controls (OR 1.91, 95% CI 1.15-3.18; P = .01). Most cases presented for anxiety (48.6%) and/ or sleep disturbance (26.1%). Conclusions Children with asthma who experienced a new-onset neuropsychiatric event had nearly twice the odds of having been prescribed montelukast in the year before their event. Clinicians should be aware of the asso- ciation between montelukast and neuropsychiatric events in children with asthma, to inform prescribing practices and clinical follow-up. (J Pediatr 2019;-:1-7). sthma affects at least 13% of children in the general population1 and up to 300 million people worldwide.2 It is marked Aby airway inflammation and recurring episodes of wheezing, dyspnea, chest tightness, and coughing.3 Asthma typically is managed with a combination of long-term maintenance therapy (maintenance medications) and short-term therapy for the relief of acute asthma symptoms (reliever medications).4 Leukotriene receptor antagonists (LTRAs), including monte- lukast, are one class of maintenance medications. LTRAs function by inhibiting inflammatory mediators of bronchoconstric- tion,5 and they are prescribed primarily as adjunct therapy to inhaled corticosteroids in patients with moderate-to-severe asthma, although they also may be prescribed as an alternative to inhaled corticosteroids for mild persistent asthma.6-8 In the US, 2.6 million children younger than the age of 16 years received dispensed prescriptions for montelukast in 2013.9 In 2009, the US Food and Drug Administration (FDA) announced a label From the 1Child Health Evaluative Sciences, The Hospital for Sick Children; 2Institute for Clinical Evaluative change for montelukast, to include a warning regarding neuropsychiatric events 3 10 Sciences; Division of Emergency Medicine, and under the “Precautions” section. The label change was spurred by postmarket- 4Clinical Pharmacology and Toxicology, The Hospital for 11 Sick Children; 5Paediatrics, Pharmacology and ing case reports to the FDA Adverse Event Reporting System. Specifically, pa- Toxicology, Faculty of Medicine, and 6Dalla Lana School tients prescribed montelukast reported episodes of depression, anxiety, sleep of Public Health, University of Toronto, Toronto, Ontario Supported by the SickKids Research Institute, Toronto, disturbance, aggression/agitation, suicidal ideation, suicide attempts, and/or Ontario. This study was also supported by the Institute 11-13 for Clinical Evaluative Sciences (ICES), which is funded completed suicide. However, subsequent studies investigating the neuropsy- by an annual grant from the Ontario Ministry of Health chiatric effects of montelukast have not defined conclusively the relationship be- and Long-Term Care (MOHLTC). The opinions, results, and conclusions reported in this paper are those of the tween montelukast and neuropsychiatric events, and the relationship between authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is in- number of montelukast prescriptions and neuropsychiatric events remains tended or should be inferred. Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions, and statements expressed herein are those of the author, and ED Emergency department not necessarily those of CIHI. The funding source had no role in the design and conduct of the study; collection, FDA US Food and Drug Administration management, analysis, and interpretation of the data; LHIN Local Health Integration Network and preparation, review, or approval of the manuscript; LTRA Leukotriene receptor antagonist and decision to submit the manuscript for publication. The authors declare no conflicts of interest. ODB Ontario Drug Benefits ON-Marg The Ontario Marginalization Index 0022-3476/$ - see front matter. ª 2019 Elsevier Inc. All rights reserved. https://doi.org/10.1016/j.jpeds.2019.02.009 1 THE JOURNAL OF PEDIATRICS www.jpeds.com Volume - - 2019 unclear.12-18 Given the serious safety signals and the high were excluded from the study cohort. Those with an prevalence of childhood asthma, we sought to investigate existing mental health condition, captured by the definition whether montelukast, a medication commonly used in pedi- of hospitalization, same-day surgery (surgical procedure atric asthma management, is associated with neuropsychi- not requiring an overnight hospital stay), or ED visit coded atric events in children. Our objective was to examine the for schizophrenia, bipolar disorder, depression/affective association between montelukast prescription and neuropsy- mood disorder, or anxiety in the year before their first chiatric events in children with asthma in Ontario, Canada. known asthma prevalence date, also were excluded from the study cohort (Table I). Cases were defined as children in the study cohort with a Methods neuropsychiatric event (defined below) between April 1, 2004, and March 31, 2016. The index date for each case A population-based, nested case–control study was conduct- was the date of their first neuropsychiatric event following ed using prescription claims and an administrative healthcare physician-diagnosed asthma. Each case was matched to a data housed at the Institute for Clinical Evaluative Sciences. maximum of 4 controls, who had no neuropsychiatric event The Ontario Drug Benefit (ODB) Database was used to during the study period, on sex, year of asthma diagnosis determine history of dispensed prescriptions. The ODB pro- (within 1 year), and year of birth (within 2 years). Controls gram offers publicly funded drug coverage for Ontario resi- were assigned the same index date as their matched case. dents receiving social assistance, residing in long-term care We employed a 1-year lookback period to ascertain history facilities, or receiving professional home care services. Chil- of asthma medication prescription. Cases and controls had dren with parents eligible for ODB also are covered under to have at least 1 record of a dispensed prescription for an the program, and their subsidized dispensed prescriptions asthma maintenance medication in ODB in the year prior are captured in the database. Prescription drugs of interest to their index date (Table II; available at www.jpeds.com). were identified using their unique Drug Identification If cases did not meet the criteria for pharmacologically Number.19 treated asthma, they were excluded; if controls did not Asthma prevalence was determined using the Ontario meet these criteria, they were returned to the pool of Asthma Surveillance Information System, which captures eligible controls to potentially be matched with a residents of Ontario diagnosed with asthma between 1996 subsequent case. Cases and controls who had a dispensed and 2015 using a validated health administrative definition: prescription for zafirlukast (another LTRA) in the year at least 1 hospitalization for asthma or 2 outpatient visits before their index date also were excluded. for asthma within 2 consecutive years.20,21 For children in Ontario, this health administrative definition for asthma Exposure and Outcome Definitions has a sensitivity of 91.4% and a specificity of 82.9%.20 The exposure of interest was dispensed prescriptions for Data on emergency department (ED) visits, hospitaliza- montelukast in the year before the index date, which was tions and same-day surgeries, and physician office visits in defined in 2 ways. Montelukast exposure was treated as a bi- Ontario were obtained from the National Ambulatory Care nary variable, based on whether the child had at least 1 Reporting System, Canadian Institute of Health Information dispensed prescription for montelukast in the year before Discharge Abstract Database, and Ontario Health Insurance the index date. In addition, montelukast exposure was Plan databases, respectively. Specific diagnoses and present- treated as a categorical variable, defined as the number of ing complaints were identified using the International Classi- dispensed prescriptions for montelukast in the year preced- fication of Diseases
Load more

Recommended publications
  • Inhibitory Activity of Pranlukast and Montelukas Against Histamine
    Showa Univ J Med Sci 21（2）, 77～84, June 2009 Original Inhibitory Activity of Pranlukast and Montelukas Against Histamine Release and LTC4 Production from Human Basophils 1, 2 1 1 Satoshi HIBINO ）, Ryoko ITO ）, Taeru KITABAYASHI ）, 1 2 Kazuo ITAHASHI ） and Toshio NAKADATE ） Abstract : Leukotriene receptor antagonists（LTRAs）are routinely used to treat bronchial asthma and are thought to act mostly by inhibiting leukotriene receptors. However, there is no preclinical or clinical evidence of the direct effect of LTRAs on histamine release from and leukotriene（LT）C4 produc- tion by basophils. We used anti-IgE antibody（Ab）, FMLP, and C5a to induce histamine release, and anti-IgE Ab and FMLP to stimulate LTC 4 production. Basophils were exposed to different concentrations of pranlukast and montelu- kast, and then to anti-IgE Ab, FMLP, and C5a. Culture supernatant histamine and LTC 4 levels were measured by using a histamine ELISA kit and a LTC 4 EIA kit, respectively. Histamine release was expressed as a percentage of the total histamine content（％HR）induced by anti-IgE Ab, FMLP, or C5a. To evaluate the effects of pranlukast and montelukast on histamine release and LTC 4 production, we calculated the percent inhibition of histamine release and LTC 4 production, expressed as percent inhibition, at different concentrations of pranlukast and montelukast. Pranlukast significantly inhibited histamine release stimulated by FMLP and C5a, but had no effect on histamine release stimulated by anti-IgE Ab. By comparison, montelukast signicantly inhibited histamine release stimulated by FMLP, C5a, and anti-IgE Ab, in a concentration-dependent manner. Both pranlukast and montelukast signicantly inhibited LTC 4 production stimulated by anti-IgE Ab and FMLP.
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    Propranolol and Gene Expression in HCT Protocol v3.0, January 15, 2016 RANDOMIZED CONTROLLED PILOT STUDY USING PROPRANOLOL TO DECREASE GENE EXPRESSION OF STRESS-MEDIATED BETA- ADRENERGIC PATHWAYS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Version 3.0 Principal Investigator: Jennifer M. Knight, MD Medical College of Wisconsin 8701 Watertown Plank Road Milwaukee, WI 53226 Telephone: 414-955-8908 Fax: 414-955-6285 Email: [email protected] Co-Investigator: J. Douglas Rizzo, MD, MS CIBMTR Froedtert and the Medical College of Wisconsin Clinical Cancer Center 9200 W. Wisconsin Avenue Suite C5500 Milwaukee, WI 53226 Telephone: 414-805-0700 Fax: 414-805-0714 Email: [email protected] Co-Investigator: Parameswaran Hari, MD, MS Froedtert and the Medical College of Wisconsin Clinical Cancer Center 9200 W. Wisconsin Avenue Suite C5500 Milwaukee, WI 53226 Telephone: 414-805-4600 Fax: 414-805-4606 Email: [email protected] Consultant Steve W. Cole, PhD and Statistician: UCLA-David Geffen School of Medicine 10833 LeConte Ave 11-934 Factor Bldg Los Angeles, CA 90095-1678 Telephone: 310-267-4243 Email: [email protected] 1 Propranolol and Gene Expression in HCT Protocol v3.0, January 15, 2016 Sponsor: Medical College of Wisconsin Funding Sponsor: This project has an offer of sponsorship from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. 2 Propranolol and Gene Expression in HCT Protocol v3.0, January 15, 2016 PROTOCOL SYNOPSIS Randomized Controlled Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant Recipients Principal Investigator: Jennifer M. Knight, MD Study Design: This is a randomized controlled pilot study designed to evaluate whether the beta-adrenergic antagonist propranolol is effective in decreasing gene expression of stress-mediated beta-adrenergic pathways among a cohort of individuals receiving an autologous hematopoietic stem cell transplant (HCT) for multiple myeloma.
    [Show full text]
  • Therapeutic Class Overview Inhaled Anticholinergics
    Therapeutic Class Overview Inhaled Anticholinergics Therapeutic Class Overview/Summary: The inhaled anticholinergics are a class of bronchodilators primarily used in the management of chronic obstructive pulmonary disease (COPD), a condition characterized by progressive airflow restrictions that are not fully reversible.1-3 Symptoms associated with COPD typically include dyspnea, cough, sputum production, wheezing and chest tightness. Specifically, inhaled anticholinergics work via the inhibition of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation. Meaningful increases in lung function can be achieved with the use of inhaled anticholinergics in patients with COPD.1-3 The available single-entity inhaled anticholinergics include aclidinium (Tudorza® Pressair), glycopyrrolate (Seebri Neohaler®), ipratropium (Atrovent®, Atrovent® HFA), tiotropium (Spiriva®, Spiriva Respimat®) and umeclidinium (Incruse Ellipta®) with the combination products including glycopyrrolate/indacaterol (Utibron Neohaler®), umeclidinium/vilanterol (Anoro Ellipta®), tiotropium/olodaterol (Stiolto Respimat®) and ipratropium/albuterol, formulated as either an inhaler (Combivent Respimat®) or nebulizer solution (DuoNeb).4-15 Ipratropium, a short-acting bronchodilator, has a duration of action of six to eight hours and requires administration four times daily. Aclidinium, glycopyrrolate, tiotropium and umeclidinium are considered long-acting bronchodilators. Aclidinium is dosed twice daily, while glycopyrrolate, tiotropium and umeclidinium
    [Show full text]
  • Olodaterol Monograph
    Olodaterol Monograph Olodaterol (Striverdi Respimat) National Drug Monograph VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a comprehensive drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechan Olodaterol is a long-acting beta2-adrenergic agonist (LABA). Binding to and activating ism of Action beta2-adrenoceptors in the airways results in stimulation of intracellular adenyl cyclase, an enzyme that mediates the synthesis of cyclic-3’, 5’ adenosine monophosphate (cAMP). Elevated levels of cAMP induce bronchodilation by relaxation of airway smooth muscle cells. Indication(s) Under Long-term once daily maintenance bronchodilator treatment of airflow obstruction in Review patients with COPD including chronic bronchitis and/or emphysema Dosage Form(s) Inhalation spray for oral inhalation via Respimat (a soft-mist inhaler) Under Review The soft-mist inhalers (SMI) provide multi-dose medication using liquid formulations similar to that used in nebulizers and are propellant-free. Presently, Respimat is the only SMI commercially available for clinical use. The soft mist is released at a slower velocity and has more prolonged spray duration than the mist produced from pressurized metered dose inhalers (pMDIs). Pressurized MDIs require coordination of actuation with inhalation which may be difficult for some patients partly due to the rapid speed at which the drug is delivered and the short duration of the mist.
    [Show full text]
  • Montelukast Sodium) Tablets, Chewable Tablets, and Oral
    Merck Sharp & Dohme Corp., a subsidiary of o MERCK & CO., INC. Whitehouse Station, NJ 08889/ USA HIGHLIGHTS OF PRESCRIBING INFORMATION .....................DOSAGE FORMS AND STRENGTHS..................... These highlights do not include all the information needed to use . SINGULAIR 10-mg Film-Coated Tablets SINGULAIR safely and effectively. See full prescribing information . SINGULAIR 5-mg and 4-mg Chewable Tablets for SINGULAIR. SINGULAIR 4.mg Oral Granules SINGULAIRiI .............................. CONTRAINDICATIONS .............................. (montelukast sodium) tablets, chewable tablets, and oral . Hypersensitivity to any component of this product (4). granules ....................... WARNINGS AND PRECAUTIONS ....................... Initial U.S. Approval: 1998 . Do not prescribe SINGULAIR to treat an acute asthma attack. .......................... RECENT MAJOR CHANGES........................... Advise patients to have appropriate rescue medication available Warnings and Precautions, Neuropsychiatric Events (5.4) 04/2010 (5.1). Inhaled corticosteroid may be reduced gradually. Do not abruptly ...........................INDICATIONS AND USAGE ........................... substitute SINGULAIR for inhaled or oral corticosteroids (5.2). SINGULAIRiI is a leukotriene receptor antagonist indicated for: . Patients with known aspirin sensitivity should continue to avoid . Prophylaxis and chronic treatment of asthma in patients aspirin or non-steroidal anti-inflammatory agents while taking 12 months of age and older (1.1). SINGULAIR (5.3). Acute prevention of exercise-induced bronchoconstriction (EIS) in Neuropsychiatric events have been reported with SINGULAIR. patients 15 years of age and older (1.2). Instruct patients to be alert for neuropsychiatric events. Evaluate Relief of symptoms of allergic rhinitis (AR): seasonal allergic the risks and benefits of continuing treatment with SINGULAIR if rhinitis (SAR) in patients 2 years of age and older, and perennial such events occur (5.4 and 6.2).
    [Show full text]
  • FDA Briefing Document Pulmonary-Allergy Drugs Advisory Committee Meeting
    FDA Briefing Document Pulmonary-Allergy Drugs Advisory Committee Meeting August 31, 2020 sNDA 209482: fluticasone furoate/umeclidinium/vilanterol fixed dose combination to reduce all-cause mortality in patients with chronic obstructive pulmonary disease NDA209482/S-0008 PADAC Clinical and Statistical Briefing Document Fluticasone furoate/umeclidinium/vilanterol fixed dose combination for all-cause mortality DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought the supplemental New Drug Application (sNDA) 209482, for fluticasone furoate/umeclidinium/vilanterol, as an inhaled fixed dose combination, for the reduction in all-cause mortality in patients with COPD, to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered
    [Show full text]
  • Long-Acting Beta-Agonists in the Management of Chronic Obstructive Pulmonary Disease: Current and Future Agents
    UCLA UCLA Previously Published Works Title Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents Permalink https://escholarship.org/uc/item/7s74p6sc Journal Respiratory Research, 11(1) ISSN 1465-9921 Authors Tashkin, Donald P Fabbri, Leonardo M Publication Date 2010-10-29 DOI http://dx.doi.org/10.1186/1465-9921-11-149 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Tashkin and Fabbri Respiratory Research 2010, 11:149 http://respiratory-research.com/content/11/1/149 REVIEW Open Access Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents Donald P Tashkin1*, Leonardo M Fabbri2 Abstract Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long-acting bronchodilators are the mainstay of therapy; as symptoms progress, guidelines recommend combining bronchodilators from different classes to improve efficacy. Inhaled long-acting b2-agonists (LABAs) have been licensed for the treatment of COPD since the late 1990s and include formoterol and salmeterol. They improve lung function, symptoms of breathlessness and exercise limita- tion, health-related quality of life, and may reduce the rate of exacerbations, although not all patients achieve clini- cally meaningful improvements in symptoms or health related quality of life. In addition, LABAs have an acceptable safety profile, and are not associated with an increased risk of respiratory mortality, although adverse effects such as palpitations and tremor may limit the dose that can be tolerated. Formoterol and salmeterol have 12-hour durations of action; however, sustained bronchodilation is desirable in COPD.
    [Show full text]
  • Singulair (Montelukast Sodium)
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use --------------------- DOSAGE FORMS AND STRENGTHS --------------------­ SINGULAIR safely and effectively. See full prescribing information SINGULAIR 10-mg Film-Coated Tablets for SINGULAIR. SINGULAIR 5-mg and 4-mg Chewable Tablets SINGULAIR 4-mg Oral Granules (3) SINGULAIR® (montelukast sodium) Tablets, Chewable Tablets, -------------------------------CONTRAINDICATIONS ------------------------------­ and Oral Granules Hypersensitivity to any component of this product (4). Initial U.S. Approval: 1998 ------------------------WARNINGS AND PRECAUTIONS-----------------------­ ---------------------------RECENT MAJOR CHANGES --------------------------­ Do not prescribe SINGULAIR to treat an acute asthma attack Indications and Usage (5.1). Exercise-Induced Bronchoconstriction (EIB) (1.2) 03/2012 Dosage and Administration Advise patients to have appropriate rescue medication available Exercise-Induced Bronchoconstriction (EIB) (2.2) 03/2012 (5.1). Inhaled corticosteroid may be reduced gradually. Do not abruptly ----------------------------INDICATIONS AND USAGE ---------------------------­ substitute SINGULAIR for inhaled or oral corticosteroids (5.2). SINGULAIR is a leukotriene receptor antagonist indicated for: Patients with known aspirin sensitivity should continue to avoid Prophylaxis and chronic treatment of asthma in patients aspirin or non-steroidal anti-inflammatory agents while taking 12 months of age and older (1.1). SINGULAIR (5.3). Acute prevention of exercise-induced bronchoconstriction (EIB) in Neuropsychiatric events have been reported with SINGULAIR. patients 6 years of age and older (1.2). Instruct patients to be alert for neuropsychiatric events. Evaluate Relief of symptoms of allergic rhinitis (AR): seasonal allergic the risks and benefits of continuing treatment with SINGULAIR if rhinitis (SAR) in patients 2 years of age and older, and perennial such events occur (5.4 and 6.2).
    [Show full text]
  • Trelegy Ellipta Patient Information
    PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PRTRELEGY ELLIPTA fluticasone furoate, umeclidinium, vilanterol dry powder for oral inhalation Read this carefully before you start taking TRELEGY ELLIPTA and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about TRELEGY ELLIPTA. What is TRELEGY ELLIPTA used for? Chronic Obstructive Pulmonary Disease (COPD): TRELEGY ELLIPTA 100 mcg/62.5 mcg/25 mcg is used in adults for the long-term treatment of a lung disease called Chronic Obstructive Pulmonary Disease or COPD. This includes chronic bronchitis and emphysema. TRELEGY ELLIPTA 100 mcg/62.5 mcg/25 mcg is used in patients who are not adequately treated by other combination medications (ICS/LABA or LAMA/LABA). TRELEGY ELLIPTA 100 mcg/62.5 mcg/25 mcg is the only strength indicated for the treatment of COPD. People with COPD are also likely to experience “flare-ups” during which their symptoms become worse. If you have a history of experiencing “flare-ups” TRELEGY ELLIPTA 100 mcg/62.5 mcg/25 mcg can help reduce the symptoms you feel when this happens. If you are a smoker, it is important to quit smoking. This will help decrease the symptoms of COPD and potentially increase your lifespan. Asthma: TRELEGY ELLIPTA 100 mcg/62.5 mcg/25 mcg and 200 mcg/62.5 mcg/25 mcg are used for the long-term treatment of asthma in people aged 18 years and older whose asthma is not well controlled with a maintenance long-acting beta2-agonist (LABA) and a medium or high dose of an inhaled corticosteroid (ICS).
    [Show full text]
  • (Lamas) a New Frontier for COPD and Asthma Treatment
    White Paper Long-Acting Muscarinic Agents (LAMAs) A New Frontier for COPD and Asthma Treatment LAMAs in Asthma and COPD Table of Contents 1. Introduction ............................................................................................. 3 2. Tiotropium Bromide ................................................................................. 4 3. Tiotropium + Olodaterol .......................................................................... 7 4. Aclidinium Bromide ................................................................................. 8 5. Aclidinium + Formoterol (ACLIFORM) ....................................................... 9 6. Glycopyrronium Bromide ....................................................................... 10 © 7. Glycopyrronium Bromide + Indacaterol (ULTIBRO )............................... 11 8. Glycopyrronium Bromide + Formoterol .................................................. 13 9. Umeclidinium ........................................................................................ 13 10. Umeclidinium + Vilanterol ..................................................................... 14 11. Triple Therapy ........................................................................................ 16 12. Conclusions ............................................................................................ 16 13. About the Author ................................................................................... 17 14. About CROMSOURCE ............................................................................
    [Show full text]
  • Once-Daily Long-Acting Beta-Agonists for Chronic Obstructive Pulmonary Disease: an Indirect Comparison of Olodaterol and Indacaterol
    International Journal of COPD Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol Neil S Roskell1 Purpose: In the absence of head-to-head clinical trials comparing the once-daily, long-acting Antonio Anzueto2 beta2-agonists olodaterol and indacaterol for the treatment of chronic obstructive pulmonary Alan Hamilton3 disease (COPD), an indirect treatment comparison by systematic review and synthesis of the Bernd Disse4 available clinical evidence was conducted. Karin Becker5 Methods: A systematic literature review of randomized, controlled clinical trials in patients with COPD was performed to evaluate the efficacy and safety of olodaterol and indacaterol. 1Statistics, Bresmed Health Network meta-analysis and adjusted indirect comparison methods were employed to evaluate Solutions Ltd, Sheffield, UK; 2 School of Medicine, University treatment efficacy, using outcomes based on trough forced expiratory volume in 1 second (FEV1), of Texas Health Science Center, Transition Dyspnea Index, St George’s Respiratory Questionnaire total score and response, San Antonio, TX, USA; 3Medical Department, Boehringer Ingelheim rescue medication use, and proportion of patients with exacerbations. (Canada) Ltd, Burlington, ON, Results: Eighteen trials were identified for meta-analysis (eight, olodaterol; ten, indacaterol). 4 Canada; Medical Department, Olodaterol trials included
    [Show full text]
  • Monteleucast and Zileuton Retard the Progression of Atherosclerosis Via Down Regulation of the Inflammatory and Oxidative Pathwa
    & Experim l e ca n i t in a l l C C f a Journal of Clinical & Experimental Hadi et al., J Clin Exp Cardiolog 2013, 4:6 o r d l i a o DOI: 10.4172/2155-9880.1000250 n l o r g u y o J Cardiology ISSN: 2155-9880 Research Article Open Access Monteleucast and Zileuton Retard the Progression of Atherosclerosis via Down Regulation of the Inflammatory and Oxidative Pathways Najah R Hadi1*, Bassim I Mohammad2, Ahmad Almudhafer1, Naser Yousif3 and Ahmed M Sultan2 1Kufa College of Medicine, Iraq 2Al-Qadesiyah University, Iraq 3Colorado University, USA Abstract Background: Atherosclerosis and its thrombotic complications are responsible for remarkably high numbers of deaths. Leukotrines are involved in different stages of atherosclerosis. Therefore this study was undertaken to evaluate the effect of montelukast and zileuton on the progression of atherosclerosis. Materials and methods: Thirty-five male rabbits were used in this study. These animals randomized into 5 groups (7 rabbits each). Rabbits in first group were maintained on normal rabbit chow diet and used as normal diet control group (NC). While the rabbits in other four groups were fed on atherogenic diet (2% cholesterol) for 8 weeks. The second group, Atherogenic Control Group (AC) rabbits received atherogenic diet alone. Third group, Positive Control Group (PC) rabbits received atherogenic diet and ethanol as vehicle. Forth group, Montelukast Treated Group (MT) rabbits received montelukast 1.5 mg per kg daily and the fifth group, Zileuton Treated Group (ZT) rabbits received zileuton 150 mg per kg daily. At the end of 8th weeks animals were sacrificed, blood sample was collected to measure the following parameters: lipid profile, plasma GSH, MDA, and hsCRP.
    [Show full text]